Surrozen Inc Ordinary Shares SRZN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $20.75
- Day Range
- $19.99–22.10
- 52-Week Range
- $8.20–35.00
- Bid/Ask
- $18.00 / $33.79
- Shares Outstanding
- 11.61M
- Market Cap
- $254.96M
- Volume/Avg
- 144,919 / 133,971
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 27.28
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 44
- Website
- https://www.surrozen.com
Valuation
|
Metric
|
SRZN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 27.28 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SRZN
|
|---|---|
Quick Ratio | 11.70 |
Current Ratio | 11.91 |
Interest Coverage | — |
Quick Ratio
SRZN
Profitability
|
Metric
|
SRZN
|
|---|---|
Return on Assets (Normalized) | −32.87% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
SRZN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|xf?$^^ | LOCK|wh!?& | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|RJ&$@v | LOCK|$qM@ | $71B | |||
| argenx SE ADR
ARGX
| LOCK|P??jzC< | LOCK|#Fw | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|QR#<%P^ | LOCK|XR& | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#y>px!J | LOCK|V^?&D | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%zqRbM@ | LOCK|$?@Mw | $26B | |||
| Moderna Inc
MRNA
| LOCK|BGvyc>N | LOCK|#Q | $25B | |||
| Incyte Corp
INCY
| LOCK|%&FdMMj | LOCK|v^ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|^%<?#?% | LOCK|&^> | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|clc^?>L | LOCK|Htq | $16B |
United States